Google
SCYX 株価分析 — Scynexis Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
SCYX に関するよくある質問
SCYXのPER（株価収益率）は？
Scynexis Inc（SCYX）は現在PER 31.37倍で取引されています。
SCYXのROE（自己資本利益率）は？
Scynexis IncのROEは-59.35%です。
SCYXの配当利回りは？
Scynexis Incの配当利回りは0.00%です。
SCYXの品質スコア（Quality Score）は？
当社のAIはSCYXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SCYXは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SCYXはどのセクターに属しますか？
Scynexis IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
SCYX AI Analysis Summary
Our AI summary for SCYX: Scynexis Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 31.37, ROE of -59.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.07
Price
0.23
(4.75%)
Day Change
|
|
|---|
SCYX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.07 |
| PBV / Sector |
9.31 / 9.54
|
| Earning Per Share | -0.32 |
| PE / Sector |
31.37 / 28.71
|
| PEG or PE/Growth / Sector |
-0.24 / -0.10
|
| Average 1M Daily Value |
1.14 M
GREAT
|
| Average 1W Daily Value |
3.62 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:02:08 |
| Symbol | SCYX |
| Name | SCYNEXIS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 79.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 384.50 / 10,605.93 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
Phone: 201 884 5485
Website: https://www.scynexis.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
